- Home
- BLRX vs PTHS Comparison
BLRX vs PTHS Comparison
Compare BLRX & PTHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- PTHS
- Stock Information
- Founded
- BLRX 2003
- PTHS 2002
- Country
- BLRX Israel
- PTHS United States
- Employees
- BLRX N/A
- PTHS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- PTHS
- Sector
- BLRX Health Care
- PTHS
- Exchange
- BLRX Nasdaq
- PTHS NYSE
- Market Cap
- BLRX 17.0M
- PTHS 17.1M
- IPO Year
- BLRX 2011
- PTHS N/A
- Fundamental
- Price
- BLRX $4.25
- PTHS $21.99
- Analyst Decision
- BLRX Strong Buy
- PTHS
- Analyst Count
- BLRX 2
- PTHS 0
- Target Price
- BLRX $19.00
- PTHS N/A
- AVG Volume (30 Days)
- BLRX 36.3K
- PTHS 175.3K
- Earning Date
- BLRX 08-14-2025
- PTHS 08-12-2025
- Dividend Yield
- BLRX N/A
- PTHS N/A
- EPS Growth
- BLRX N/A
- PTHS N/A
- EPS
- BLRX N/A
- PTHS N/A
- Revenue
- BLRX $22,340,000.00
- PTHS N/A
- Revenue This Year
- BLRX N/A
- PTHS N/A
- Revenue Next Year
- BLRX N/A
- PTHS N/A
- P/E Ratio
- BLRX N/A
- PTHS N/A
- Revenue Growth
- BLRX 91.68
- PTHS N/A
- 52 Week Low
- BLRX $2.30
- PTHS $4.50
- 52 Week High
- BLRX $35.60
- PTHS $54.29
- Technical
- Relative Strength Index (RSI)
- BLRX 43.97
- PTHS N/A
- Support Level
- BLRX $4.47
- PTHS N/A
- Resistance Level
- BLRX $4.75
- PTHS N/A
- Average True Range (ATR)
- BLRX 0.30
- PTHS 0.00
- MACD
- BLRX -0.04
- PTHS 0.00
- Stochastic Oscillator
- BLRX 11.96
- PTHS 0.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About PTHS PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.